COPD and biomarkers: The search goes on

Thorax

Volumn 63, Issue 12, 2008, Pages 1032-1034

  Turino, Gerard M ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CLARA CELL PROTEIN; CLARA CELL SECRETORY PROTEIN 16; UNCLASSIFIED DRUG;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CLARA CELL; EDITORIAL; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION;

EID: 57149101772     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thx.2008.105957     Document Type: Editorial

References (29)

1. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008;31:416-69.
2. Lomas DA, Silverman EK, Edwards LD, et al. Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort. Thorax 2008;63:1058-63.
3. Umland TC, Swaminathan S, Singh G, et al. Structure of a human Clara cell phospholipid binding protein-ligand complex at 1.9 A resolution. Nat Struct Biol 1994;8:538-45.
4. Yoneda K. Ultrastructural localization of phospholipases in the Clara cell of the rat bronchiole. Am J Pathol 1978;93:745-52.
5. Van Vyve T, Chanez P, Bernard A, et al. Protein content in bronchoalveolar lavage fluid of patients with asthma and control subjects. J Allergy Clin Immunol 1995;95:60-8.
6. Shijubo N, Itoh Y, Yamaguchi T, et al. Serum and BAL Clara cell 10 kDa protein (CC10) levels and CC10-positive bronchiolar cells are decreased in smokers, Eur Respir J 1997;10:1108-14.
7. Lakind JS, Holgate ST, Ownby DR, et al. A critical review of the use of Clara cell secretory protein (CC 16) as a biomarker of acute or chronic pulmonary effects. Biomariters 2007;12:445-67.
8. Jorans PG, Sibelle Y, Goilding NJ, et al. Potential role of Clara cell protein, an endogenous phospholipase A2 inhibitor, in acute lung injury, Eur Respir J 1995;8:1647-53.
9. Vestbo J, Anderson W, Coxson HO, et al. Evaluation of COPO Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE), Eur Respir J 2008;31:869-73.
10. Bernard A, Hermans C. Biomonitoring of early effects on the kidney or lung: the science of the total environment. Sci Total Environ 1997;199:205-11.
11. Agusti AG, Noguera A, Sauleda J, et al. Systemic effects of chronic obstructive pulmonary disease, Eur Respir J 2003;21:347- 60.
12. de Torres JP, Cordoba-Lanus E, Lopez-Aguilar C. et al. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients, Eur Respir J 2006;27:902-7.
13. Dev D, Wallace E, Sankaran R, et al. Value of C-reactive protein measurements in exacerbations of chronic obstructive pulmonary disease. Respir Med 1998;92:664-7.
14. Dahl M, Vestbo J, Lange P, et al. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:250-5.
15. Keatings VM, Collins PD, Scott DM, et al. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996;153:530-4.
16. Burrows BJ, Bloom JW, Traver GA, et al. The course and prognosis of different forms of chronic airway obstruction in a sample from the general population. N Engl J Med 1987;317:1309-14.
17. Schriver EE, Davidson JM, Sutcliffe MC, et al. Comparison of elastin peptide concentrations in body fluids from healthy volunteers, smokers, and patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1992;145:762-6.
18. Stone JP, Glottlieb DJ, O'Connor GT, et al. Elastin and collagen degradation products in urine of smokers with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;151:952-9.
19. Ma S, Lin YY, Turino GM. Measurements of desmosine and isodesmosine by mass spectrometry in COPD. Chest 2007;131:1363-71.
20. Boschetto P, Quintavalle S, Zeni E, et al. Markers of emphysema are associated with more severe chronic obstructive pulmonary disease. Thorax 2006;61:1037-42.
21. Viglio S, Annovazzi L, Luisetti M, et al. Progress in the methodological strategies for the detection in real samples of desmosine and isodesmosine, two biological markers of elastin degradation. J Sep Sci 2007;30:202-13.
22. Cantor JO, Cerreta JM, Ochoa M, et al. Aerosolized hyaluronan limits airspace enlargement in a mouse model of cigarette smoke-induced pulmonary emphysema, Exp Lung Res 2005;31:417-30.
23. Ma S, Lin YY, Turino GM. The effect of tiotropium (TIO) on levels of desmosine and isodesmosine (D/I) in urine, plasma, and sputum in COPD (abstract). Eur Respir J 2007;30(Suppl 51):355s.
24. Parr DG. White AJ, Bayley DL, et al. Inflammation in sputum relates to progression of disease in subjects with COPD: a prospective descriptive study. Respir Res 2006;7:136.
25. Donaldson GC, Seemungal TAR, Patel IS, et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 2005;128:1995-2004.
26. Fogarty A, Jones S. Britton JR, et al. Systemic inflammation and decline in lung function in a general population: a prospective study. Thorax 2007;62:515-20.
27. American Thoracic Society/European Respiratory Society. Standards for the diagnosis and management of individuals with alpha-1-antitrypsin deficiency. Am J Respir Crit Care Med 2003;168:818-900.
28. DeMeo DL Sandhaus RA, Barker AF, et al. Determinants of airflow obstruction in severe alpha-1-antitrypsin deficiency. Thorax 2007;62:806-13.
29. DeMeo DL Campbell EJ, Barker AF, et al. IL10 polymorphisms are associated with airflow obstruction in severe alpha 1-antitrypsin deficiency. Am J Respir Cell Mol Biol 2008;38:114-20.